On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following retinal vein occlusion (RVO) with up to every 8-week dosing after an initial monthly dosing period.RVO is a blockage in one of the veins that drain blood from the retina, causing blood and fluid to leak and potentially leading to vision loss.The FDA also approved a monthly dosing option for some patients who may bene ...